SALL2 and breast carcinoma: Of relevance here is 5-azacitidine, a DNMTi (DNA methyltransferase inhibitor), which triggered SALL2 restoration and sensitized tamoxifen-resistant breast cancer to tamoxifen therapy in vivo [54].